The financing round was led by RT Ventures and will support the US commercial roll-out of the company test.
"This Series B financing allows us to commercialize our lead product in patients with advanced lung cancer, following our positive reimbursement decision. We also have an exciting portfolio of future products that will be advanced in parallel to maximize the benefits of our industry-leading InVision Liquid Biopsy platform to patients. We are grateful to our existing investors for their continued support and are delighted to welcome RT Ventures to our already strong investor base. With these funds in place, we look forward to continuing our mission to transform the lives of cancer patients through the power of liquid biopsy."
The financing values the synthetic biology business at £30.5m post-money.
"This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering. Through our continued investment in automation and optimising our commercialisation strategy, we aim to maximise shareholder value and exceed our ambitious growth targets. Throughout our journey, Mercia’s investment model has been pivotal to Oxford Genetics’ current success. The ability to leverage capital and continued support from Mercia via seed stage through to later investment rounds has enabled us to attract excellent syndicate investors onto our share register. We are excited to welcome Canaccord Genuity onto our share register alongside Invesco Asset Management and look forward to working with all of our investors to grow the business over the coming years."
Parkwalk Advisors backs GeoSpock with £2m in new funding to support international expansion.
"We are delighted to announce the addition of Noren to our Board of Directors at this exciting period of growth for GeoSpock. I am hugely impressed with the wealth of knowledge and experience Noren brings to our business, and his expertise will be instrumental in helping to guide the continued expansion and success of GeoSpock. We also thank Parkwalk Advisors for their continued support as we strive to achieve our technological vision across industries spanning mobility, telco, and IoT, as well as smart city and maritime initiatives."
Apiary Capital has acquired a majority stake in G3 Comms to fund organic expansion and acquisitions.
"Thanks to the efforts of the exceptional G3 Comms team, the last few years have seen our revenues and profit grow year-on-year and we are now perfectly positioned to move forward with our long-term strategic plan. Apiary’s experience and supporting investment will be instrumental in fulfilling that plan."
